Drug Profile
Research programme: cancer immunotherapeutics - Transimmune Biotech
Alternative Names: MAR based antibody and cell therapy - Transimmune BiotechLatest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Transimmune Biotech
- Class Antibodies; Antivirals; CAR-T cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours; Viral infections
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Haematological-malignancies in China (Parenteral)
- 28 May 2020 No recent reports of development identified for research development in Solid-tumours in China (Parenteral)
- 28 May 2020 No recent reports of development identified for research development in Viral-infections in China (Parenteral)